# TABLE OF CONTENTS

## WHAT WE DO
- What is the mandate of the REB? .................................................. 2
- What is the scope of activities of the CHEO REB? .................. 2
- A snapshot of the review process ................................................. 3

## WHAT WE’VE DONE
- 2022 Highlights ........................................................................ 4
- Oversight and Compliance ......................................................... 4
- Governance ................................................................................. 4
- Operations ................................................................................ 4
- Figure 1 .................................................................................... 5
- Figure 2 .................................................................................... 5
- Figure 3 .................................................................................... 5
- Figure 4 .................................................................................... 6
- Figure 5 .................................................................................... 6

## WHERE WE’RE GOING
- 2022 Strategic Goals .................................................................. 7
- 2022 Governance and Operational Objectives .................. 7

## WHO WE ARE
- Research Ethics Board ................................................................. 8
- Research Ethics Office ................................................................. 9
WHAT WE DO

What is the mandate of the REB?

The CHEO REB is an oversight body that determines the ethical acceptability of the design and conduct of human research conducted under the auspices of CHEO to fundamentally protect the rights and dignity of research participants and to pragmatically protect the institution from liability. To that end, the REB reviews and approves studies to ensure they meet and comply with the highest scientific and ethical standards, including proposing modifications, monitoring safety, determining remediation for protocol deviations, serious adverse events, or non-compliance, and/or rejecting or terminating any proposed or ongoing unethical or non-compliant research. The REB functions independently of the Hospital and Research Institute with respect to all deliberations and decisions.

Why it matters

A fundamental premise of standards governing the ethical conduct of research is that research can benefit human society. Researchers have the primary responsibility to ensure that research involving humans meets high scientific and ethical standards that respect and protect the dignity and welfare of participants. Research, by definition, is a process of discovery. It necessarily entails or increases risk to participants and others. Risks can be trivial or profound, physical or psychological, individual or communal. There are many tragic examples where research participants and communities have been harmed by research. To minimize the risks of such harms, ethical principles and guidelines play an important role in advancing the pursuit of knowledge in a responsible and respectful manner.

Having robust processes and appropriate safeguards to ensure compliance with the necessary ethical and regulatory requirements for human research is a shared institutional responsibility.

What is the scope of activities of the CHEO REB?
2 TYPES OF REVIEW

**Full Board Reviews**
Full Board reviews involve greater than minimal risk to the participant. This includes studies involving regulated drugs or clinical research with vulnerable populations.

**Delegated Reviews**
Delegated reviews involve minimal risk to the participant. This includes prospective and retrospective studies with children, families and/or staff.

Submissions, especially delegated submissions, significantly vary in complexity and quality. They may be investigator- or learner-led, unfunded, and not peer-reviewed for their scientific viability.

THE REVIEW PROCESS

1. **Submission to REB**
   - For example:
     - New applications
     - Modifications
     - Annual renewals
     - Protocol deviations
     - Serious adverse events

2. **Review of all study documentation based on ethical, regulatory, administrative requirements**
   - For delegated studies, minimum 2 reviewers
   - For greater than minimal risk studies, Full Board

3. **Develop and synthesize feedback, send to research team**

4. **Review of Investigator Response and revised study documentation**

5. **Approve or provide additional feedback (repeat until approval)**

Throughout the review process:

- Administrative review of all submissions for completeness and accuracy of study documentation
- Discussions/meetings with PIs and research teams
- Consultation with Quality Assurance, Privacy, other REBs, research ethics colleagues
- Risk management and mitigation to preserve the scientific and ethical integrity of studies and the research enterprise at CHEO

WHAT WE DO

A SNAPSHOT OF THE REVIEW PROCESS
WHAT WE’VE DONE

2022 HIGHLIGHTS

OVERSIGHT AND COMPLIANCE

**1041**
Oversight of 1041 active studies

**207**
New studies

**1497**
Post approval activities

**693**
Annual renewals

**100+**
Over 100+ meetings with PIs and research teams

**195**
New delegated studies reviewed by Chair and Research Ethics Office

**12**
New greater than minimal risk studies reviewed by the Full Board

**367**
Modifications

**33**
CTO Board of Record for 33 provincial and 70+ centre applications¹

**3500+**
Over 3500+ hours reviewing studies

GOVERNANCE

- Created new position (Research Ethics Officer), and recruited a new Manager, and 3 new REB members
- Supported upscaling of REB membership proficiency in key topics in research ethics by providing multiple education and training opportunities
- Continued to streamline and enhance review and approval processes through existing and new harmonization agreements (e.g., Ottawa Health Sciences Network, Royal Ottawa Hospital)
- Participating in the development of oversight mechanisms for all quality improvement (QI) activities
- Participating in the national pilot pediatric ethics review program (CHEER); Board of Record for multiple CHEER studies involving sites across Canada

OPERATIONS

- Continued to streamline and optimize operations of the Research Ethics Office to ensure the successful and efficient administration of the human research protections program at CHEO
- Established new and updated existing standardized templates and guidance to support high quality research development
- Restructured the initial submission process to reduce administrative burden through streamlining application forms and reducing mandatory documentation relating to validated tools
- Supported the ongoing enhancement of the CHEO RI institutional approval process (START SMART)

¹ Clinical Trials Ontario’s (CTO) streamlined system enables a single CTO-qualified REB to provide ethics review and ongoing oversight for multiple research sites participating in the same study. The CHEO REB became a qualified Board of Record in 2017.
FIGURE 1: Review and Approval Timeline Greater than Minimal Risk 2022

Division of timeline from submission to approval

- REB 16%
- PI 84%

Submission to First Feedback
2 median days

Submission to Final Approval
84 median days

FIGURE 2: Review and Approval Timeline Prospective Minimal Risk 2022

Division of timeline from submission to approval

- REB 23%
- PI 77%

Submission to First Feedback
5 median days

Submission to Final Approval
30 median days

FIGURE 3: Review and Approval Timeline Retrospective Minimal Risk 2022

Division of timeline from submission to approval

- REB 25%
- PI 75%

Submission to First Feedback
2 median days

Submission to Final Approval
12 median days
### WHAT WE’VE DONE

#### FIGURE 4: New study submissions (Initial Applications)

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegated Prospective</td>
<td>91</td>
</tr>
<tr>
<td>Delegated Retrospective</td>
<td>61</td>
</tr>
<tr>
<td>Prescribed Entity/Prescribed Registry</td>
<td>10</td>
</tr>
<tr>
<td>Full Board</td>
<td>12</td>
</tr>
<tr>
<td>CTO</td>
<td>33</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>207</td>
</tr>
</tbody>
</table>

#### FIGURE 5: Post-approval activities

<table>
<thead>
<tr>
<th>Category</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Renewals</td>
<td>693</td>
</tr>
<tr>
<td>Modifications</td>
<td>367</td>
</tr>
<tr>
<td>Study Closures</td>
<td>163</td>
</tr>
<tr>
<td>Study Closures (Requested by REB)</td>
<td>24</td>
</tr>
<tr>
<td>Protocol Deviations</td>
<td>148</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>61</td>
</tr>
<tr>
<td>Serious Adverse Events</td>
<td>5</td>
</tr>
<tr>
<td>Change in Study Status</td>
<td>34</td>
</tr>
<tr>
<td>Privacy Incidents</td>
<td>2</td>
</tr>
<tr>
<td>Incidents of Non-compliance</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>1497</td>
</tr>
</tbody>
</table>
WHERE WE’RE GOING

2023 STRATEGIC GOALS

- Implement structural and operational changes to augment governance best practices, oversight, and compliance to bolster a well-functioning and compliant human research protections program at CHEO
- Increase support and resources for the REB to address resource and efficiency gaps to align REB capacity with the growing research enterprise at CHEO
- Improve REB and institutional accountability and effectiveness to be congruent with CHEO’s Safety First philosophy
- Partner with external stakeholders to drive provincial and national projects forward, and position CHEO REB as a frontrunner in the Canadian research ethics community

2023 GOVERNANCE AND OPERATIONAL OBJECTIVES

1. Support the development of resources and processes to facilitate the conduct of Indigenous health research in a culturally appropriate manner and respect Indigenous data sovereignty

2. Develop a robust research ethics education and training program to support research teams to apply requirements in collaboration with the CHEO RI

3. Update institutional policies on the ethical conduct of research, Terms of Reference, and Standard Operating Procedures in collaboration with the CHEO RI

4. Bolster professional development opportunities for REB members to stay current with evolving research ethics standards and culture
Cécile Bensimon MA, PhD
Cécile is Chair of the CHEO REB and Director of Ethics and Professional Affairs at the Canadian Medical Association. She has acted as an ethics advisor on pandemic ethics, most recently on the Ontario COVID-19 Bioethics Table. She is a member of the CIHR Committee on Ethics and RCPC Ethics Committee, and editor of the Canadian Journal of Bioethics.

Sandra Djuric RN, MScN
Sandy completed her nursing studies at the University of Ottawa where she graduated with a Master of Science in Nursing. In her career at CHEO she worked in Pediatric Medicine, Oncology and Discharge Planning. She is a long-standing Faculty member at the University of Ottawa where she teaches courses in Community Health and Professionalism and Ethics.

Sabrina Heyde JD
Sabrina holds a law degree from Queen’s University and works as a Senior Investigator for the Office of the Privacy Commissioner of Canada. She has served as a community/legal member of the CHEO REB since 2017, and as a legal consultant to the Canadian Pediatric Surveillance Program since 2020.

Sophia Hrycko PhD, MD, FRCP(C)
Sophia is a child and adolescent psychiatrist at CHEO and Assistant Professor at the University of Ottawa since 1998. She works on the Consultation-Liaison service.

Marie-Ange Janvier PhD
Marie-Ange is a certified clinical engineer (CCE) at CHEO. She is a part-time professor at the University of Ottawa in the biomedical engineering program. She is an Adjunct Research Professor at Carleton University in the Department of Systems and Computer Engineering and an Adjunct Professor at the University of Ottawa in the Department of Mechanical Engineering.

Robert Klaassen MD, FRCP(C)
Robert is a Pediatric Hematologist/Oncologist at CHEO, Professor at the Department of Pediatrics, University of Ottawa and Clinical Investigator at the CHEO Research Institute. His clinical focus is on the care of patients with non-malignant hematologic disorders.

Elaine Leung MD, FRCP(C)
Elaine is a dually trained Pediatric Hematologist/Oncologist and Hemopathologist. She joined CHEO’s Department of Laboratory Medicine in 2006, and has served as the Head of the Division of Hematology and Transfusion Medicine since 2014.

Claudia Malic MD, MRCs(Eng), FRCS (Plast), MD(res), FRCS
Claudia has been caring for plastic surgery and burn patients at CHEO since 2014. She served as the Director of Research for Plastic Surgery (2016-2021) and was appointed in 2021 as Vice-Chair of Quality and Patient Safety for the Department of Surgery, University of Ottawa, where she is also an Associate Professor.

Siddika Mithani PhD
Siddika holds a BSc in Pharmacy and a PhD in psychopharmacology. She is the past President of the Public Health Agency of Canada as well as the Canadian Food Inspection Agency. She has extensive background and experience in the regulatory and scientific review, evaluation, and approval of clinical trials in Canada.

Scott Murray Hon BA
Scott is the President, DataAngel Policy Research Inc., a Canadian policy research company serving a broad range of clients. Prior, he was Director, Education Outcomes at the Unesco Institute for Statistics (UIS). Scott holds an Honors BA from the University of Western Ontario.
WHO WE ARE

Lori Pope
Lori Pope is a community member of the REB. She is the mother of two children, both of whom were treated for life-threatening medical conditions at CHEO. She is also a lawyer who has worked in private practice, legal aid clinics, and for a federal regulatory tribunal. She has a particular interest in human rights, privacy, and community legal education.

Régis Vaillancourt
OMM, CD, PharmD, FCSHP
Régis was the Director of Pharmacy at CHEO for 16 years. Throughout his career, Régis has worked with different pharmacy organizations. He has published more than 100 peer-reviewed articles on pharmacy practice with a focus on medication safety and health literacy.

Sarah Tagliapietra
HBSc, BEd
Sarah is the incoming Manager of the CHEO REB. She has worked with multiple academic and community based REBs in Ontario for over 10 years, and also has experience in global clinical trial management.

Natalie Anderson
Natalie is the Research Ethics Officer of the CHEO REB and brings a wealth of experience as a longstanding member of the Research Ethics Office.

Yulia Rosenstein Levin
PhD
Yulia is the Research Ethics Coordinator of the CHEO REB. She has expertise in academic administration and a background in conducting human participant research in the areas of Cognitive Psychology and Behavioral Sciences.

RESEARCH ETHICS OFFICE

Valerie Bourada
MSc
Valerie is the outgoing Manager of the CHEO REB. She holds a Master’s degree in Science from the University of Ottawa. Her career has been linked to health care research, starting as a clinical research coordinator in Oncology.

Ellen Song
Ellen is a former CHEO patient and former member of the CHEO-RI’s Patient and Family Advisory Committee. She is also a medical student at the University of Ottawa Faculty of Medicine.

Valerie Bourada
MSc
Valerie is the outgoing Manager of the CHEO REB. She holds a Master’s degree in Science from the University of Ottawa. Her career has been linked to health care research, starting as a clinical research coordinator in Oncology.

Ellen Song
Ellen is a former CHEO patient and former member of the CHEO-RI’s Patient and Family Advisory Committee. She is also a medical student at the University of Ottawa Faculty of Medicine.